Answers are grounded in this paper and cite their sources.
In vitro evaluation demonstrates yeast cell wall enhances growth and metabolite production in lactic acid bacteria, suggesting its potential as a sustainable prebiotic.
Saccharomyces cerevisiae yeast cell wall (SC), a fermentation by-product rich in β-glucans, mannans, and mannoproteins, was evaluated as a sustainable microbial-derived prebiotic for Lacticaseibacillus paracasei, Lacticaseibacillus rhamnosus, and Levilactobacillus brevis. FTIR confirmed the characteristic structure of SC. Its effects on probiotic functionality were assessed through growth kinetics, biomass production, antimicrobial, antioxidant, enzymatic, and organic acid analyses, using MRS and inulin as controls. SC significantly enhanced biomass production, with the highest yield obtained for L. paracasei in 10% SC (5.85 g), compared with 3.75 g in MRS. L. rhamnosus showed superior antimicrobial activity in SC supplemented medium and inhibited Escherichia coli and Staphylococcus aureus (up to 4 mm), while L. paracasei exhibited 76.06% DPPH scavenging activity. L. rhamnosus showed the highest lipase (5.80 U/mL) and lactic acid (11.80 g/L) production, whereas L. brevis produced the highest acetic (0.56 g/L) and butyric acids (0.0050 g/L). These findings demonstrated that SC is a promising sustainable microbial-derived prebiotic for synbiotic fermentation and valorization of industrial yeast by-products.
No takes yet. Share an insight, caveat, or question.
Soyer et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: